Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 18, 2025 07:20 ET | Source: F2G, Ltd.

F2G Announces Publication in The Lancet Infectious Diseases of Phase 2b Data Demonstrating Positive Therapeutic Responses in Patients with Serious Invasive Fungal Diseases Treated with Oral Olorofim

MANCHESTER, United Kingdom, June 18, 2025 (GLOBE NEWSWIRE) -- F2G Ltd, a clinical-stage biopharmaceutical company developing olorofim, a novel therapy to treat life-threatening rare fungal...
September 12, 2024 07:00 ET | Source: F2G, Ltd.

F2G Announces $100 Million Financing to Advance Late-Stage Development and Commercialization of Novel Antifungal Drug Candidate Olorofim in the US

Financing is being led by new investor AMR Action Fund with strong participation from new investor ICG Life Sciences and existing investors MANCHESTER, United Kingdom, Sept. 12, 2024 (GLOBE...
October 21, 2023 08:30 ET | Source: F2G, Ltd.

F2G and Shionogi Present Full Data Set from Pivotal Phase 2b Study at Trends in Medical Mycology (TIMM) 2023 Demonstrating Positive Therapeutic Responses in Patients with Invasive Fungal Infections Treated with Oral Olorofim

An overall success rate of 28.7% was seen at day 42, the primary endpoint, and 27.2% at day 84, as determined by a data review committee (DRC) using the EORTC-MSG criteriaThe success rate rose to...
June 19, 2023 07:30 ET | Source: F2G, Ltd.

F2G Receives Complete Response Letter from FDA for New Drug Application for Olorofim for The Treatment of Invasive Fungal Infections; Plans Resubmission With Additional Data and Analyses

Complete Response Letter is related to the request for additional data and analyses.F2G remains committed to bringing olorofim to patients and intends to meet with FDA in the coming months to align on...
March 17, 2023 08:45 ET | Source: F2G, Ltd.

UPDATE – F2G Wins Investment Deal of the Year Bionow 2022 Award

MANCHESTER, United Kingdom, March 17, 2023 (GLOBE NEWSWIRE) -- F2G Ltd. today announced the company has been awarded a prestigious Bionow award in recognition of its contributions to the North...
March 17, 2023 07:30 ET | Source: F2G, Ltd.

F2G Wins Investment Deal of the Year Bionow 2022 Award

MANCHESTER, United Kingdom, March 17, 2023 (GLOBE NEWSWIRE) -- F2G Ltd. today announced the company has been awarded a prestigious Bionow award in recognition of its contributions to the North...
January 05, 2023 07:30 ET | Source: F2G, Ltd.

F2G to Present at Biotech Showcase™ 2023

MANCHESTER, United Kingdom, Jan. 05, 2023 (GLOBE NEWSWIRE) -- F2G Ltd. today announced that the Company’s chief executive officer, Francesco Lavino will provide a corporate overview at Biotech...
December 19, 2022 03:00 ET | Source: F2G, Ltd.

F2G Announces FDA Filing Acceptance of New Drug Application for Olorofim for the Treatment of Invasive Fungal Infections

Application submitted under priority review with PDUFA target action date set for June 17, 2023NDA submission is based on positive data from ongoing Phase 2b open-label study of oral olorofim in 100...
October 21, 2022 11:30 ET | Source: F2G, Ltd.

F2G Announces Data from Phase 2b Study at ID Week 2022 Showing Positive Therapeutic Response in Patients with Invasive Fungal Infections Treated with Olorofim

Data are based on analysis of the first 100 patients from an ongoing Phase 2b study of patients who have limited or no treatment options for invasive fungal infectionsOverall, a 44% response rate,...
October 13, 2022 10:00 ET | Source: F2G, Ltd.

F2G to Present Interim Results from Phase 2B Open Label Study of Olorofim in Invasive Fungal Infections at IDWeek 2022

MANCHESTER, United Kingdom, Oct. 13, 2022 (GLOBE NEWSWIRE) -- F2G Ltd, a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat...